>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
达格列净对老年2型糖尿病患者肾功能和钙磷代谢的影响
作者:孙婧  苏爱梅 
单位:南京鼓楼医院 老年科, 江苏 南京 210008
关键词:2型糖尿病 老年人 肾功能 达格列净 钙磷代谢 
分类号:R587.1;R592
出版年·卷·期(页码):2021·40·第六期(840-842)
摘要:

目的: 探讨老年2型糖尿病患者加用达格列净后对肾功能和钙磷代谢的影响。方法: 回顾性分析2018年1月至2020年9月于我院就诊的45例老年2型糖尿病患者的临床资料, 比较加用达格列净治疗前后肾功能相关指标及钙磷代谢指标。结果: 与治疗前相比, 加用达格列净后治疗后血肌酐明显降低, 肾小球滤过率明显升高(P < 0.05), 血尿素氮、血尿酸无明显差异(P > 0.05);钙磷代谢方面, 血钙明显升高(P < 0.05), 血磷无明显变化(P > 0.05)。结论: 达格列净在老年2型糖尿病患者治疗过程中, 可降低患者血肌酐, 增加肾小球滤过率, 有较好的肾脏保护作用。关于钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂与钙、磷代谢及骨代谢相关指标的关系有待进一步研究和完善。

Objective: To investigate the effects of dapagliflozin on renal function and calcium-phosphorus metabolism in elderly patients with type 2 diabetes.Methods: The clinical date of forty-five elderly patients with type 2 diabetes in our hospital from January 2018 to September 2020 were retrospectively analyzed.Estimated glomerular filtration rate (eGFR), uric acid, serum creatinine(Scr), blood urea nitrogen(BUN), serum calcium, serum phosphate before and after treatment with dapagliflozin were compared.Results: After the treatment, patients' Scr was lower than before, eGFR and serum calcium were higher than before, and the differences were statistically significant (all P < 0.05). There was no significant difference in uric acid and serum phophate (P > 0.05).Conclusion: Dapagliflozin can effectively reduce Scr, increase eGFR. The renal protective function of dapagliflozin in elderly patients with type 2 diabetes was defined. The relationship among dapagliflozin and calcium-phosphorus metabolism, bone metabolism needs more study.

参考文献:

[1] 朱大龙, 母义民. 中国成人2型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J]. 中华内分泌代谢杂志, 2020, 36(6): 458-468.
[2] WIVIOTT S D, RAZ I, BONACA M P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357.
[3] HEERSPINK H J, PERKINS B A, FITCHETT D H. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications[J]. Circulation, 2016, 134(10): 752-772.
[4] BARNETT A H, MITHAL A, MANASSIE J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2014, 2(5): 369-384.
[5] FIORETTO P, STEFANSSON B V, JOHNSSON E, et al. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment[J]. Diabetologia, 2016, 59(9): 2036-2039.
[6] 袁小利, 王守俊. 达格列净对2型糖尿病肾病患者的临床疗效[J]. 河南医学研究, 2020, 29(11): 1969-1971.
[7] XIN Y, GUO Y, LI Y, et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis[J]. Saudi J Biol Sci, 2019, 26(2): 421-426.
[8] TAYLOR S I, BLAU J E, ROTHER K I. Possible adverse effects of SGLT2 inhibitors on bone[J]. Lancet Diabetes Endocrinol, 2015, 3(1): 8-10.
[9] NAUCK M A, DEL PRATO S, MEIER J J, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial[J]. Diabetes Care, 2011, 34(9): 2015-2022.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405848 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364